International Journal of Radiation Research

en Influencing Factors on the clinical effect of yishenhuoxue detoxification method combined with bortezomib-lenalidomide-dexamethasone (VRD) regimen and radiotherapy in the treatment of multiple myeloma Radiation Biology Radiation Biology <div style="text-align: justify;">Background: To evaluate factors influencing the clinical efficacy of radiotherapy combined with the Yishenhuoxue detoxification (YSHX-D) method and the bortezomib-lenalidomide-dexamethasone (VRD) regimen in multiple myeloma (MM). Materials and Methods: From February 2021 to November 2022, 100 MM patients were enrolled in the Department of Hematology and Oncology at Langfang Traditional Chinese Medicine Hospital. Diagnosis was confirmed through bone marrow examination and immunological index analysis. Patients were randomly assigned to two groups (n=50 each). The observation group received radiotherapy with YSHX-D plus VRD, while the control group received radiotherapy with VRD alone. Radiotherapy was delivered to symptomatic bone lesions to relieve pain and stabilize disease progression. Clinical indicators included M protein, immunoglobulins, haemoglobin, platelets, and white blood cells. Treatment response was assessed per International Myeloma Working Group (IMWG) criteria. Results: Both groups achieved pain relief and slowed lesion progression with radiotherapy. The observation group demonstrated higher response rates than the control group, with greater reductions in M protein and immunoglobulins and improvements in haemoglobin and platelet counts (P<0.05). Logistic regression identified disease stage, age, genetic factors, and immune status as independent predictors of treatment efficacy. Conclusion: Radiotherapy combined with YSHX-D and VRD is safe and effective for MM, especially for managing skeletal complications. Patient-specific factors significantly influence outcomes, underscoring the need for individualized treatment strategies.</div> Multiple myeloma, radiotherapy, bortezomib, lenalidomide, dexamethasone, medicine, Chinese traditional. 391 396 http://ijrr.com/browse.php?a_code=A-10-1-1506&slc_lang=en&sid=1 M.S. Wang 7900319475328460033478 7900319475328460033478 No Second Department of Hematology, Langfang Traditional Chinese Medicine Hospital, Langfang, 065000, China Y.Q. Li hengshuilyq@126.com 7900319475328460033479 7900319475328460033479 Yes Second Department of Hematology, Langfang Traditional Chinese Medicine Hospital, Langfang, 065000, China E.C. Gao 7900319475328460033480 7900319475328460033480 No Second Department of Hematology, Langfang Traditional Chinese Medicine Hospital, Langfang, 065000, China Y.C. Zhou 7900319475328460033481 7900319475328460033481 No Second Department of Hematology, Langfang Traditional Chinese Medicine Hospital, Langfang, 065000, China H. Fan 7900319475328460033482 7900319475328460033482 No Second Department of Hematology, Langfang Traditional Chinese Medicine Hospital, Langfang, 065000, China Z.H. Zhou 7900319475328460033483 7900319475328460033483 No Second Department of Hematology, Langfang Traditional Chinese Medicine Hospital, Langfang, 065000, China S.L. Yang 7900319475328460033484 7900319475328460033484 No Second Department of Hematology, Langfang Traditional Chinese Medicine Hospital, Langfang, 065000, China C.Y. Sun 7900319475328460033485 7900319475328460033485 No Second Department of Hematology, Langfang Traditional Chinese Medicine Hospital, Langfang, 065000, China